Income statement
USD
Annual
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 217K |
| Gross Profit | 0 | 0 | 0 | 0 | 101K |
| Operating Income | -851K | -74K | -57K | -173K | -808K |
| EBITDA | -851K | 108K | -57K | 64K | -598K |
| Net Income | -897K | -87K | -438K | -1M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0026
+0.00% today
1Y Change
-49.02%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Stemsation International, Inc. (STSN) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 49.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +122.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +122.6%, free cash flow +21.0% with operating margin 0.0% and ROIC -1.8%. Stock Foundry combines STSN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
STSN
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
STSN Max Drawdown
-84.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for STSN and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$217.1K
FY Net Income
-$1.0M
+9.4% YoY
Free Cash Flow
-$685.4K
+10.5% YoY
Revenue Growth
+0.0%
EPS Growth
+122.6%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 217K |
| Gross Profit | 0 | 0 | 0 | 0 | 101K |
| Operating Income | -851K | -74K | -57K | -173K | -808K |
| EBITDA | -851K | 108K | -57K | 64K | -598K |
| Net Income | -897K | -87K | -438K | -1M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4K | 961 | 10K | 10K | 18K |
| Total Assets | 13M | 43K | 59K | 79K | 80K |
| Total Liabilities | 2M | 725K | 912K | 977K | 311K |
| Shareholder Equity | 11M | -682K | -853K | -898K | -230K |
| Total Debt | 1M | 282K | 461K | 214K | 99K |
| Net Debt | 1M | 281K | 451K | 214K | 82K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
685K
+10.5% YoY
Capital Expenditures
0
-100.0% YoY
Free Cash Flow
685K
+10.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-2.5%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.